[Skip to Navigation]
January 1965

Treatment of Epidemic Keratoconjunctivitis With Idoxuridine (IUDR)

Author Affiliations

Philadelphia and San Francisco
From the Research Department of the Wills Eye Hospital (Drs. Hecht and Sery), and the Department of Microbiology, University of California Medical Center (Dr. Jawetz and Miss Hanna).

Arch Ophthalmol. 1965;73(1):49-54. doi:10.1001/archopht.1965.00970030051012

A small outbreak of epidemic keratoconjunctivitis was seen at the Wills Hospital in the winter of 1962-1963. Eight inpatients and ten outpatients were involved. The symptoms and signs of each fit the many previous EKC descriptions in the literature. To the extent of our knowledge, it was the third appearance of the disease in Philadelphia in 13 years.1

Adenovirus type 8 has been well established as the principal and most important etiologic agent of typical epidemic keratoconjunctivitis.2 Isolation of this virus from early cases of the disease and rises in specific neutralizing antibody titer can provide specific laboratory confirmation of the clinical impression.

Adenoviruses are DNA viruses and thus may be susceptible to inhibitors of DNA synthesis, such as idoxuridine (5-iodo-2'deoxyuridine; IUDR). Kaufman3 introduced this drug for the treatment of another DNA-virus infection, herpes simplex. A number of reports indicate the clinical efficacy of idoxuridine in suppressing